FindTrial
Sign In

Receptor Antagonist in the Treatment of Allergic Rhinitis

Use of Leukotriene Receptor Antagonist in the Treatment of Allergic Rhinitis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-09000688
Enrollment
Unknown
Registered
2009-11-26
Start date
2006-10-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

asthma, allergic rhinitis

Interventions

Two groups:Montelukast 26 weeks per subject versus placebo

Sponsors

Prof. Albert Martin Li
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
6 Years to 18 Years

Inclusion criteria

Inclusion criteria: Include: Patient from 6-18 yrs old with asthma and allergic rhinitis

Exclusion criteria

Exclusion criteria: Exclude: Subject with congenital nasal anomalies or had received systemically administered corticosteroids within 1 month of enrollment.

Design outcomes

Primary

MeasureTime frame
The primary outcome measures include nasal cytokine levels, nasal airflow and daily rhinitis scores.;—

Secondary

MeasureTime frame
Secondary outcomes measures include symptom-free days, blood eosinophil counts and spirometric parameters.;—

Countries

China

Contacts

Public ContactProf. A.M Li
albertmli@cuhk.edu.hk+852 26360020

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026